Pregenerate GmbH specializes in using scalable organ-on-a-chip models to understand how cartilage cells respond to inflammation and various treatments. This innovative technology, known as OptimateOA™, aims to stratify patients into targeted treatment subgroups and identify the best treatment for each patient's specific arthritis needs. Additionally, it helps pharmaceutical companies save billions of dollars by improving drug success rates and replacing animal testing with human cell testing.